A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorBlokhin's Russian Cancer Research Center
About this trial
This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
Eligibility criteria
Qualifiers
Patients aged over 18 years old.
Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
Patients has received Trastuzumab Deruxtecan
Available medical history.
Disqualifiers
Incomplete medical history.
Pregnancy or breast-breeding
Trial design
Treatments tested in this trial
- T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days.
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov